Philippe Herman

Founder & CEO, IMMUNOCHEM

I have been evolving for +12 years on the intersection of biophysics and computational biology.
I authored 20 papers studying microbial adhesion using the atomic force microscope.
I had the chance to apply it to the fabulous world of microbes.
I discovered and demonstrated key concepts in protein-host protein interactions for staphylococcal proteins.
I notably wrote a PNAS paper in 2018 and was invited to write a Science perspective around the hospital-acquired infections.
I am passionate about how technique can help Science. During my research, I needed of precisely designed molecules against my antigens of interests.
This led me to discover the power of VHH, and inspired me to develop IMMUNOCHEM’s EVOBodies™ platform and BactoTerminator™ new therapeutic approach to fight against AMR, making them accessible to our clients.